V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210002838 | 210006312 | null | 102.5 | null | 2017-03-17 | 2017-04-08 | FEC + DOCETAXEL | N | null | FEC + DOCETAXEL | 101752604 |
| 210002839 | 210006313 | 1.65 | 63.8 | Palliative (P) | 2018-12-05 | 2018-12-26 | Carboplatin + Docetaxel | null | N | CMF | 100661655 |
| 210002840 | 210006314 | 1.63 | 77.7 | null | 2016-06-09 | 2016-06-24 | FEC 100 | null | null | FEC | 101817323 |
| 210002842 | 210006316 | null | null | null | null | 2019-02-03 | null | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 101791004 |
| 210002844 | 210006318 | null | 103 | null | 2017-09-04 | 2017-09-04 | FEC + DOCETAXEL | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 101044268 |
| 210002850 | 210006321 | 1.62 | 55.3 | null | 2017-09-21 | 2017-10-12 | FEC + DOCETAXEL | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100707337 |
| 210002854 | 210006323 | 1.64 | 88.9 | null | null | 2017-05-29 | FEC + DOCETAXEL | null | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100773920 |
| 210002857 | 210006325 | 1.51 | 77.9 | Palliative (P) | 2017-02-09 | 2017-02-09 | FEC 100 | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100075132 |
| 210002858 | 210006326 | 1.57 | 49.75 | Adjuvant (A) | null | 2020-01-27 | EC | null | N | EC | 100017670 |
| 210002859 | 210006327 | null | null | null | 2018-09-24 | 2018-10-10 | FEC | N | null | FEC | 100814918 |
| 210002861 | 210006328 | 1.67 | 66.2 | Neo-adjuvant (N) | 2018-03-26 | 2018-04-01 | Epirubicin (weekly) | N | N | CARBOPLATIN + DOCETAXEL | 101578111 |
| 210002862 | 210006329 | 1.68 | 72.2 | Neo-adjuvant (N) | null | 2018-10-05 | EC | null | N | EC | 101200039 |
| 210002863 | 210006330 | 1.67 | 94 | Adjuvant (A) | 2019-12-03 | 2019-12-11 | null | 02 | N | CISPLATIN + ETOPOSIDE | 100688876 |
| 210002865 | 210006332 | 1.58 | null | Palliative (P) | 2014-07-27 | 2014-08-11 | FEC 60 or 75 | N | N | FEC | 101795163 |
| 210002867 | 210006334 | 1.6 | 57.45 | Palliative (P) | 2018-06-24 | 2018-07-09 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | N | N | ABEMACICLIB + FULVESTRANT | 100232881 |
| 210002868 | 210006335 | 1.74 | 42.4 | Palliative (P) | 2019-09-02 | 2019-09-22 | FEC + DOCETAXEL | N | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 101234987 |
| 210002870 | 210006337 | 1.64 | 73.4 | null | null | 2018-10-13 | FEC + DOCETAXEL | null | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100198080 |
| 210002872 | 210006339 | 0 | 61.2 | Adjuvant (A) | 2016-09-17 | 2016-10-08 | FEC + DOCETAXEL | null | N | FEC + DOCETAXEL | 100224710 |
| 210002875 | 210006341 | 1.62 | 58.9 | Palliative (P) | null | 2020-12-25 | Paclitaxel+Trastuzumab wkly Maint | null | null | PACLITAXEL + TRASTUZUMAB | 101308267 |
| 210002876 | 210006342 | null | null | null | null | 2018-01-22 | FEC 100 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100271841 |
| 210002877 | 210006343 | 1.57 | 83.5 | Neo-adjuvant (N) | null | 2016-05-15 | Liposomal Doxorubicin (Caelyx) | null | N | ATEZOLIZUMAB + NAB-PACLITAXEL | 100456101 |
| 210002878 | 210006344 | 1.6 | 119.7 | null | 2016-02-29 | 2016-03-04 | EC | 01 | null | EC | 101006110 |
| 210002880 | 210006346 | null | null | null | 2019-10-06 | 2019-10-07 | FEC + DOCETAXEL | N | null | FEC + DOCETAXEL | 100257081 |
| 210002884 | 210006348 | null | null | null | 2017-04-05 | 2017-04-20 | Paclitaxel+Trastuzumab wkly Maint | null | null | PACLITAXEL + TRASTUZUMAB | 100946010 |
| 210002886 | 210006349 | 0 | 89.4 | Palliative (P) | 2016-12-23 | 2017-01-01 | TRASTUZUMAB EMTANSINE | null | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100675150 |
| 210002887 | 210006350 | null | null | null | null | 2019-02-07 | Capecitabine | 02 | null | CAPECITABINE | 101533304 |
| 210002891 | 210006352 | 1.61 | null | Palliative (P) | 2016-12-02 | 2016-12-10 | null | 02 | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101792681 |
| 210002892 | 210006353 | null | 80.8 | null | null | 2018-09-23 | null | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101089523 |
| 210002893 | 210006354 | null | null | Curative (C) | null | 2018-12-08 | FEC 100 | 02 | N | FEC | 100497400 |
| 210002895 | 210006356 | 1.56 | 121.8 | Adjuvant (A) | 2017-07-10 | 2017-07-31 | FEC 60 or 75 | 02 | N | FEC | 101293646 |
| 210002899 | 210006358 | 1.74 | 76.9 | Neo-adjuvant (N) | 2019-11-30 | 2019-12-22 | Liposomal Doxorubicin (Caelyx) | null | N | ROSCO TRIAL | 101464667 |
| 210002900 | 210006359 | null | null | null | 2017-04-03 | 2017-05-08 | null | 02 | null | FEC + DOCETAXEL | 100015149 |
| 210002901 | 210006360 | 1.71 | 98.7 | null | 2019-11-14 | 2019-11-27 | FEC | 02 | null | FEC | 100685754 |
| 210002904 | 210006362 | 1.61 | 50.7 | null | 2017-05-22 | 2017-05-23 | FEC 100 | null | null | FEC | 100036885 |
| 210002906 | 210006364 | null | null | null | null | 2018-07-13 | EC | null | null | EC | 100885329 |
| 210002910 | 210006366 | 1.5 | 40.1 | Adjuvant (A) | 2018-06-20 | 2018-07-11 | Paclitaxel+Trastuzumab wkly Maint | null | N | PACLITAXEL + TRASTUZUMAB | 100774139 |
| 210002911 | 210006367 | 1.62 | 74.2 | Adjuvant (A) | null | 2016-07-30 | SACITUZUMAB GOVITECAN | 02 | N | ROSCO TRIAL | 101261700 |
| 210002915 | 210006370 | 1.64 | 69 | Adjuvant (A) | null | 2019-08-16 | null | 02 | null | CAPECITABINE | 101163156 |
| 210002917 | 210006372 | null | null | null | 2018-03-27 | 2018-03-28 | FEC 60 or 75 | N | null | FEC | 101308691 |
| 210002920 | 210006373 | 1.69 | 0 | null | 2018-04-13 | 2018-04-13 | FEC | null | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 101155828 |
| 210002921 | 210006374 | 1.49 | 81.7 | Palliative (P) | 2019-05-02 | 2019-05-22 | FEC 100 | N | N | FEC | 101822744 |
| 210002924 | 210006377 | null | null | null | 2016-09-28 | 2016-10-05 | FEC 100 | N | null | FEC | 101550346 |
| 210002925 | 210006378 | 1.49 | 57.8 | Neo-adjuvant (N) | 2022-05-10 | 2022-05-10 | EC | null | N | EC | 101151301 |
| 210002926 | 210006379 | 1.69 | 72.4 | Adjuvant (A) | 2015-12-12 | 2016-03-17 | Paclitaxel+Trastuzumab wkly Maint | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 101170018 |
| 210002927 | 210006380 | 1.77 | 77.8 | Adjuvant (A) | 2020-11-13 | 2021-02-14 | FEC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100597936 |
| 210002929 | 210006381 | null | null | null | 2019-10-17 | 2019-10-18 | FEC + DOCETAXEL | 02 | null | FEC + DOCETAXEL | 100868610 |
| 210002930 | 210006382 | 1.68 | 64.5 | null | 2018-08-24 | 2018-09-09 | Trial Unspecified | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100581865 |
| 210002932 | 210006384 | 1.64 | 124.4 | Disease modification (D) | 2019-02-06 | 2019-02-07 | Carboplatin + Docetaxel | null | N | LETROZOLE + PALBOCICLIB | 100613122 |
| 210002934 | 210006385 | 1.56 | 0 | Palliative (P) | 2018-12-31 | 2019-01-08 | AC | 02 | N | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 101563824 |
| 210002937 | 210006387 | 1.62 | 62.8 | Adjuvant (A) | null | 2019-10-19 | EC | null | N | EC | 101655869 |